Search: WFRF:(Ekman Carl)
> (1975-1999) >
A randomized prospe...
A randomized prospective study comparing long-term intravesical instillations of mitomycin-c and BCG in patients with superficial bladder carcinoma
- Article/chapterEnglish1996
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-58975
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-58975URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
PURPOSE: We compared the efficacy and toxicity of long-term mitomycin C versus bacillus Calmette-Guerin (BCG) instillation in patients at high risk for recurrence and progression of superficial bladder carcinoma. MATERIALS AND METHODS: Our randomized comparison study included 261 patients with primary dysplasia, or stage Tis, stage T1, grade 3 and multiple recurrent stage Ta/T1, grade 1 or 2 disease. Mitomycin C (40 mg.) or Pasteur strain BCG (120 mg.) was instilled weekly for 6 weeks, then monthly for up to 1 year and every 3 months during year 2. RESULTS: After a median followup of 39 months 49% of the patients given BCG and 34% given mitomycin C were disease-free (p < 0.03), compared to 48 and 35%, respectively, of those with stage Ta or T1 disease, and 54 and 33%, respectively, of those with dysplasia or stage Tis tumor. Tumor progressed in 13% of patients, with no statistically significant difference observed regarding progression between the mitomycin C and BCG groups. Side effects were more common after BCG instillation, with 5 cases of severe side effects compared to 1 in the mitomycin C group. Treatment was stopped due to toxicity in 10% of the patients. CONCLUSIONS: The majority of patients tolerated long-term intravesical therapy well. BCG instillation was hampered by more frequent side effects. BCG was superior regarding recurrence prophylaxis, since patients given BCG had fewer recurrences and a significantly longer time to treatment failure compared to those treated with mitomycin C. No statistically significant difference was observed regarding progression.
Added entries (persons, corporate bodies, meetings, titles ...)
-
Norlen, Bo JohanUppsala universitet,Institutionen för kirurgiska vetenskaper,Urology
(author)
-
Ekman, Peter
(author)
-
Johansson, StaffanUppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi(Swepub:uu)sjo23772
(author)
-
Lagerkvist, Mikael
(author)
-
Lindeborg, Torsten
(author)
-
Olsson, Jan Olov
(author)
-
Tveter, Kjell
(author)
-
Wijkstrom, Hans
(author)
-
Westberg, Ronny
(author)
-
Malmstrom, Per-UnoUppsala universitet,Institutionen för kirurgiska vetenskaper,Urology
(author)
-
Uppsala universitetInstitutionen för kirurgiska vetenskaper
(creator_code:org_t)
Related titles
-
In:Journal of Urology156:2, s. 372-3760022-53471527-3792
Internet link
Find in a library
To the university's database
- By the author/editor
-
Lundholm, Carl
-
Norlen, Bo Johan
-
Ekman, Peter
-
Johansson, Staff ...
-
Lagerkvist, Mika ...
-
Lindeborg, Torst ...
-
show more...
-
Olsson, Jan Olov
-
Tveter, Kjell
-
Wijkstrom, Hans
-
Westberg, Ronny
-
Malmstrom, Per-U ...
-
show less...
- Articles in the publication
-
Journal of Urolo ...
- By the university
-
Uppsala University